Tumor mutational burden predicts neoantigen profiles and immunotherapy response in microsatellite stable tumors across different cancer types
These findings support the clinical relevance of TMB as a biomarker for neoantigen prediction and immunotherapy-relevant features in MSS tumors.
Authors
- Olesia Kondrateva (ORCID: https://orcid.org/0000-0001-6220-5077)
- Maria O. Anisimova
- Tugce Bilgin Sonay
- Inti Zlobec
Institutions
- University of Bern (CH)
- SIB Swiss Institute of Bioinformatics (CH)
- ZHAW Zurich University of Applied Sciences (CH)
- Life Science Zurich (CH)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.3389/fimmu.2025.1582464
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00